FDA Engagement and Approval Process
's COVID-19 vaccine is progressing towards full approval following additional discussions, with the agency requesting a plan for further clinical data collection.
The FDA's acting commissioner paused the decision, amid concerns of political interference and a recent leadership change at the FDA, sparking debates over vaccine safety.
Vaccine Technology and Market Impact
Novavax's vaccine, the only traditional protein-based COVID-19 vaccine in the , differs from mRNA vaccines by using lab-grown spike proteins to stimulate an immune response.
The announcement of potential full approval led to a significant surge in Novavax's stock, reflecting investor optimism and resolving previous concerns about regulatory delays.